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Summary The tumour-associated antigen epithelial glycoprotein-2 (EGP-2) is a promising target for detection and treatment of a variety of
human carcinomas. Antibodies to this antigen have been successfully used in patients for imaging of small-cell lung cancer and for adjuvant
treatment of minimal residual disease of colon cancer. We describe here the isolation and complete characterization of high-affinity single-
chain variable fragments (scFv) to the EGP-2 antigen. First, the binding kinetics of four murine whole antibodies directed to EGP-2 (17-1A,
323/A3, MOC-31 and MOC-161) were determined using surface plasmon resonance (SPR). The MOC-31 antibody has the lowest apparent
off-rate, followed by MOC-161 and 323/A3. The V-genes of the two MOC hybridomas were cloned as scFv in a phage display vector and
antigen-binding phage were selected by panning on recombinant antigen. The scFvs compete with the original hybridoma antibodies for
binding to antigen and specifically bind to human carcinomas in immunohistochemistry. MOC-31 scFv has an off-rate which is better than
those of the bivalent 17-1A and 323/A3 whole antibodies, providing it with an essential characteristic for tumour retention in vivo. The
availability of these high-affinity anti-EGP-2 antibody fragments and of their encoding V-genes creates a variety of possibilities for their future
use as tumour-targeting vehicles.
Keywords: epithelial glycoprotein-2; tumour targeting; single-chain Fv; affinity; phage display
During colorectal carcinogenesis, a number of (membrane) anti-
gens are up-regulated, mutated or differently processed, providing
targets for (adjuvant) immunotherapy of the disease. Several
tumour antigens have been described and used for targeting or
as indicators of progression of disease [e.g. carcinoembryonic
antigen (CEA), TAG72, c-erB2, (underglycosylated) MUC-1,
p53]. The epithelial glycoprotein-2 (EGP-2, also named C017-lA
antigen, KSA, EGP40 or Ep-CAM) is a tumour-associated antigen
present on human simple epithelia and their derived tumours. The
abundant expression ofEGP-2 on a number ofhuman carcinomas,
its limited expression on the luminal side ofnormal non-squamous
epithelia only and the fact that it is not shed into the circulation
make this antigen a favourable target for imaging and
immunotherapy of cancer. Murine antibodies to EGP-2 have been
used in radioimmune detection trials (Balaban et al, 1991;
Kosterink et al, 1995), as well as in phase I and II clinical trials
(Frodin et al, 1988). The most successful study has been the treat-
ment of minimal residual disease (MRD) in patients with Dukes'
C colon carcinoma using the 17-1A antibody (Herlyn et al, 1979).
In this study (Riethmuller et al, 1994), an overall 30% reduction
in 5-year mortality was observed, proving that passive
Received 21 October 1997
Revised 19 February 1998
Accepted 24 February 1998
Correspondence to: HR Hoogenboom, CESAME at Department of Pathology,
University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, The
Netherlands
immunotherapy in an adjuvant setting may be as effective as
chemotherapy.
Other therapeutic strategies based on the use of antibodies to
EGP-2 have also been described. These include the recruitment
and activation of T cells by using a fusion of an EGP-2-reactive
antibody fragment with the bacterial superantigen staphylococcal
enterotoxin A (Dohlsten et al, 1994) or by using bispecific anti-
bodies, directed to both EGP-2 and the T-cell CD3 antigen
(Kroesen et al, 1994). In a different approach, the conjugation
of anti-EGP-2 antibodies to different bacterial toxins has been
shown to yield potent immunotoxins (LeMaistre et al, 1987;
Zimmermann et al, 1997). These (pre)clinical studies all underline
the possibilities ofusing antibodies (in different format) to EGP-2
for (adjuvant) immunotherapy.
Careful experimental analysis of scFv variants ofan anti-c-erB2
antibody with a range of affinities indicated that there is a clear
correlation between affinity increase and enhanced tumour reten-
tion (Adams et al, 1993). The availability ofhigh-affinity recombi-
nant anti-EGP-2 antibody fragments would therefore be highly
desirable. Indeed, the potential use of such scFv antibody frag-
ments for imaging ofhuman carcinomas has already been demon-
strated with a scFv directed to carcinoembryonic antigen (CEA;
Begent et al, 1996).
In this study, we first compared the binding kinetics of four
murine whole antibodies [17-lA, 323/A3 (Edwards et al, 1986)
MOC-31 and MOC-161 (Souhami et al, 1988)] to the antigen
EGP-2 using SPR in a BlAcore. Our results show that the MOC-
31 antibody has by far the lowest off-rate of all antibodies tested;
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MOC-161 has a similar off-rate to the 323/A3 antibody. The V-
genes of the two antibodies with lowest off-rate (MOC-31 and
MOC-161) were cloned in scFv format and the off-rate and speci-
ficity of the scFv antibody fragments determined. These high-
affinity anti-EGP-2 scFvs may have important applications in
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Figure 1 Kinetic measurements using SPR in a BlAcore. Sensorgrams
showing association and dissociation of different anti-EGP-2 antibodies and
antibody fragments: (A) whole antibodies (1, 17-1A; 2, chimeric 17-1A; 3,
323/A3; 4, MOC-31; 5, Bis-1) and (B) antibody fragments (1, MOC-31 scFv;
2, MOC-161 scFv) to the antigen coated to the surface of a sensor chip.
Association starts at t= 130 s; dissociation starts at t= 310 s
imaging and possibly immunotherapy of different human carci-
nomas and may provide useful building blocks for further rational
therapeutic antibody design.
MATERIALS AND METHODS
Anti-EGP-2 antibodies
The antibodies 17-lA, chimeric 17-lA and 323/A3 were a kind
gift from Dr SO Warnaar (Centocor, Leiden, The Netherlands).
The two hybridomas cloned in this study [MOC-31 (IgGl/K) and
MOC-161 (IgG2aIK)] were generated by hybridoma technology
(Souhami et al, 1988). Bis-1 bispecific antibody (Kroesen et al,
1994) is produced by a quadroma clone made from the
hybridomas MOC-31 (anti EGP-2) and RIV-9 (anti CD3) and
was kindly donated by Dr B-J Kroesen (University Hospital
Groningen).
Kinetic measurement using SPR in a BlAcore
Recombinant EGP-2 was expressed in the baculovirus system as
described [Strassburg et al, 1992; Helfrich et al, 1994; a kind gift
of Professor D Herlyn (the Wistar Institute)]. The antigen was
covalently coupled to a CM-5 sensorchip (Pharmacia, Uppsala,
Sweden) via free amide chemistry, resulting in a surface of 350
resonance units (RU). All kinetic measurements were performed
on this antigen surface. To determine the binding kinetics of
different whole antibodies (17-lA, chimeric 17-lA, 323/A3,
MOC-161, MOC-31 and Bis-1) and antibody fragments (MOC-31
scFv and MOC-161 scFv), this 'low-density' EGP-2 surface was
saturated with antibody (at 200 nM) or antibody fragment using a
flow rate of 5 ,ul min-' (Figure 1). Dissociation rates (K0) were
then calculated using the BlAevaluation software (Pharmacia)
from the sensorgrams depicted in Figure 1. The off-rates were
determined by curve fitting on the time interval t = 315-320 s,
with one exception: because of its very low value, it was impos-
sible to determine the off-rate of the MOC-31 whole antibody in
this time period. In this case, an average value of three indepen-
dentfittings on different parts ofthe curve is given. As the kinetics
ofbinding ofthe MOC-161 whole antibody were determined with
concentrated hybridoma supernatant, the antibody concentration
was unknown and the sensorgram is not shown. However, the
same experimental set-up was used, in which the antigen surface
was saturated with antibody. All measurements were carried out at
room temperature.
Table 1 Kinetic data and affinities of anti-EGP-2 antibodies and antibody fragments
K.. Ko Ko K.
Antibody (105 M-1 s-1) (10-3 s-1) ± s.e. (10-3 s-1) ± s.e. (108 M-1) t,,2
± s.e. (monovalent) (bivalent)
17-1A 5.95 ± 0.28 - 38.2± 1.2a ND 18 s
Chimeric 17-1A 10.9 ± 0.2 - 58.3± 2.2a ND 12 s
323/A3 2.51 ± 0.29 - 1.06 ± 0.02 ND 10 min 54 s
Bis-1 0.48 ± 0.03 0.25 ± 0.03 - 1.92 46 min 13 s
MOC-31 1.06±0.16 - 0.05±0.01 4.24 3h 51 min 03s
MOC-161 ND - 1.55 ± 0.01 ND 7 min 27 s
MOC-31 scFv ND 0.34 ± 0.05 - ND 33 min 59 s
MOC-161 scFv ND 2.05±0.08 - ND 5min 38s
aBecause of the very high off-rates of these antibodies, the low-density EGP-2 surface could not be saturated with antibody (Figure 1). These off-rates are
therefore understimations of the true values, which may account for the unexpectedly observed difference.
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Table 2 Oligonucleotides used for cloning of murine V-genes
(a) Primers used for the primary amplification of VH
MVH1BACK: 5'-AGG T(C/G)(A/C) A(A/G)C TGC AG(C/G) AGT C(A/T)G G-3'
MVH1 FOR-2: 5'-TGA GGA GAC GGT GAC CGT GGT CCC TTG GCC CC-3'
(b) Primers used for the primary amplification of VL
MVKBACKmix; an equimolar mix of:
-MVKABACK: 5'-GAT GTT TTG ATG ACC CM ACT CCA-3'
-MVKCBACK: 5'-GAC ATT GTG CT(A/G) ACC CA(A/G) TCT CCA-3'
-MVKDBACK: 5'-GAC ATC CAG ATG AC(T/C/G/A) CAG TCT CCA-3'
-MVKEBACK: 5'-CAA AUT GTT CTC ACC CAG TCT CCA-3'
-MVKFBACK: 5'-GAA AAT GTG CTC ACC CAG TCT CCA-3'
MVKFOR4; an equimolar mix of:
-MJKIFONX; 5'-CCG TU GAT TTC CAG CTT GGT GCC-3'
-MJK2FONX: 5'-CCG UT TAT UTC CAG CTT GGT CCC-3'
-MJK4FONX: 5'-CCG UTT TAT TTC CAA CTT TGT CCC-3'
-MJK5FONX: 5'-CCG UTT CAG CTC CAG CUr GGT CCC-3'
(e) Primers for the synthesis ofthe linkerfragment
MLINKBACK: 5'-GGG ACC ACG GTC AC C GTC TCC TCA-3'
MLINKFORmix; an equimolar mix of:
-MLINK-A-FOR: 5'-TGG AGT TTG GGT CAT CAA AAC ATC CGA TCC GCC ACC GCC AGA GCC-3'
-MLINK-C-FOR: 5'-TGG AGA CTG GGT (T/C)AG CAC AAT GTC CGA TCC GCC ACC GCC AGA-3'
-MLINK-D-FOR: 5'-TGG AGA CTG NGT CAT CTG GAT GTC CGA TCC GCC ACC GCC AGA GCC-3'
-MLINK-E-FOR: 5'-TGG AGA CTG GGT GAG AAC AAT TTG CGA TCC GCC ACC GCC AGA GCC-3'
-MLINK-F-FOR: 5'-TGG AGA CTG GGT GAG CAC AUT TTC CGA TCC GCC ACC GCC AGA GCC-3'
(d) Re-amplification primers (to introduce restriction sites in the assembled cassette: sequences encoding restriction sites are underlined)
MVHIBACKSFI; (introduces a SM site at the 3' end of the assembled scFv cassette):
5'-CAT GCC ATG ACT CGC GGC CCA GCC GGC CAT GGC C(C/G)A GGT (C/G)(A/C)A (A/G)CT GCA G(C/G)A GTC (A/T)GG-3'
MVK4FORNOT (introduces a Nofi site at the 5' end of the assembled scFv cassette): an equimolar mix of:
-MJK1 FORNOT: 5'-GAG TCA TTC TCG ACT TGC GGC CGC CCG UT GAT TTC CAG CTT GGT GCC-3'
-MJK2FORNOT: 5'-GAG TCA TTC TCG ACT TGC GGC CGC CCG UT TATUTC CAG CTT GGT CCC-3'
-MJK4FORNOT: 5'-GAG TCA UTC TCG ACT TGC GGC CGC CCG UT TAT TTC CAA CTT TGT CCC-3'
-MJK5FORNOT: 5'-GAG TCA TTC TCG ACT TGC GGC CGC CCG UTT CAG CTC CAG CUT GGT CCC-3'
Forsequencing
pUC-FOR: 5'-CGA CGT TGT AAA ACG ACG GCC AGT-3'
pUC-REVERSE: 5'-CAG GAA ACA GCT ATG AC-3'
Association rates (Kon) were determined from a plot of [Ks =
(Kon x C + Koff)] vs antibody concentration (C). Briefly, antibodies
were run over the low-density antigen surface at different concen-
trations and Ks values were determined using the BlAevaluation
software. From a plot of the obtained Ks values as function of C,
Kor values were obtained by linear fitting as the slope ofthe curve.
The half-life of the antibody-antigen complex was calculated as
t12 = 1n2/Koff (Table 1).
Cloning vectors
pCANTAB6 is a derivative ofpHENI (Hoogenboom et al, 1991),
carrying an additional stretch of six histidine residues [to allow
immobilized metal ion affinity chromatography (IMAC) purifica-
tion] upstream of the c-myc-derived sequence (which allows
detection with the 9E10 antibody). ScFv cassettes are cloned as
SfiI-NotI fragments in frame with the upstream pelB leader
sequence and LacZ promoter and with the downstream bacterio-
phage gene III. The vector also contains an amber stop codon
between the c-myc sequence and gene III, allowing production of
soluble scFv in a non-suppressor strain of Escherichia coli.
Plasmid pUCI19-polyHIS6myc (a kind gift from Dr AD Griffiths)
is a derivative of pUC119 and carries 5'-SfiI/NcoI and 3'-NotI
cloning sites. ScFv cassettes are cloned in frame with an upstream
LacZ promoter and pelB signal sequence and a downstream
cassette ofa c-myc-derived sequence and six histidine residues. As
in the related pUC119-His6mycXba (Griffiths et al, 1994), the
bacteriophage gene III is absent.
Escherichia colistrain
TG1: K12, D(lac-pro), supE, thi, hsdD5IF' traD36,proA+B+, laclq,
lacZDM15
Oligonucleotides
Primers used for the amplification of variable parts of the heavy
chain (VH) and ofthe light chain (VL) ofmurine immunoglobulin
genes, for the synthesis ofthe linker fragment and for reamplifica-
tion of the assembled scFv cassettes are listed in Table 2. All
primers were purchased from Eurogentec (Liege, Belgium).
Cloning of immunoglobulin genes
Total cellular RNA was extracted from 107 cells of each of the
hybridoma cell lines MOC-31 and MOC-161 by means of the
RNazol method (Biotecx Laboratories, Houston, TY, USA). After
precipitation, the RNA was dissolved in 20 ,l ofwater and used as
template to synthesize cDNA using random hexamer primers
(Promega, Madison, WJ, USA) in a 50-gl reverse transcriptase
(RT) reaction according to standard procedures. Variable domains
ofboth heavy (VH) and light chain (VL) genes were then amplified
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from cDNA using heavy of light chain-specific primer mixes (see
Table 2) and assembled with a linker sequence encoding a 15-
residue Gly/Ser sequence by means of Splice Overlap Extension
PCR, as described by Clackson et al (1991). The assembled
cassette was gel purified, cut with the restriction enzymes Sfil and
NotI and gel purified again. ScFv cassettes were cloned into
Sfi1NotI-digested pCANTAB6 DNA and the ligation mix was elec-
troporated into E. coli TGI using standard procedures. Bacteria
were plated on 2xTY [1.6% (w/v) trypton, 1% (w/v) yeast extract,
0.5% (w/v) sodium chloride] plates, supplemented with 2% (w/v)
glucose and 100gg ml-l ampicillin, and harvested after overnight
growth to form a library oftransformants.
Selection on recombinant, baculovirus-expressed
EGP-2 by panning in immunotubes
A small repertoire of transformed bacteria (approximately 106 in
size) containing the MOC-31 scFv ligated into pCANTAB6 was
rescued with helper phage M13K07 and phage were panned for
binding to the antigen EGP-2 [coated at 10gg ml' concentration
using immunotubes (Maxisorb; Nunc/Life Technologies,
Gaithersburg, ND, USA)] as described previously (Marks et al,
1991). Two rounds of selection were performed; after each round,
single clones were screened for binding to antigen in enzyme-
linked immunosorbent assay (ELISA) as described (see below).
ELISA and competition ELISA
To identify binding scFvs from the individual clones selected for
further analysis, an ELISA using soluble scFv was performed on
purified, recombinant EGP-2. Individual bacterial clones were
picked andproduction ofsoluble scFv was induced by activation of
the upstream LacZ promoter with isopropyl-p-D-thiogalactopyra-
noside (IPTG) as described by Marks et al (1991). ELISA plates
(Costar, Cambridge, MA, USA) were coated overnight with
1 jg ml EGP-2 in phosphate-buffered saline (PBS), washed three
times with PBS-T [PBS, 0.5% (v/v) Tween-20], three times with
PBS and blocked for 1 h at room temperature (RT) with 2% MPBS
[2% (w/v) Marvel - skimmed milk powder - in PBS]. After
blocking, induced bacterial supernatants were added [50% (v/v) in
2% MPBS] and incubated for 1.5 h at RT. Bound antibody frag-
ments were detected with the 9E10 antibody [50% (v/v) hybridoma
supernatant in 2% MPBS], peroxidase-conjugated rabbit anti-
mouse immunoglobulins [Dako, Glostrup, Denmark; 0.1% (v/v) in
2% MPBS] and stained with trimethylbenzidine (TMB) and
hydrogen peroxide. Optical density was measured at 450 nm.
For competition ELISA, scFv antibody fragments expressed as
pIll fusions on the tip of bacteriophage were detected in the pres-
ence of excess whole antibody (because ofcross-reactivity ofanti-
mouse Ig antibodies - used to detect the 9E10 antibody bound to
scFvs - with the original whole murine antibodies, this test was not
performed with soluble scFvs). Briefly, MOC-31 and MOC-161
phage were rescued with helper phage M13KO7 as described
previously (Marks et al, 1991). Approximately 1010 colony-forming
units (cfu) of phage were then mixed with 100 jl of hybridoma
supernatant and simultaneously added to different wells of an
antigen-coated ELISA plate. Bound phage were detected with a
sheep polyclonal antiserum [sheep anti-fd; Pharmacia; 0.02% (v/v)
in 2% MPBS], peroxidase-conjugated rabbit anti-goat immuno-
globulins [Dako, Glostrup, Denmark; 0.05% (v/v) in 2% MPBS]
and stained with TMB/hydrogen peroxide.
Sequencing
The nucleotide sequences of both the MOC-31 and MOC-161
scFvs were determined using the dideoxy sequencing method
of Sanger. Products of the sequencing reaction were analysed
on a semiautomated sequencer (Alf Express; Pharmacia).
Oligonucleotides used were pUC-FOR and pUC-REV (Table 2).
Production and purification of soluble scFv
To produce large quantities of both antibody fragments, scFv
cassettes were subcloned as SfiI/Not I fragments into
pUC-119polyHIS6myc, lacking the bacteriophage gene III. This
expression plasmid is less toxic to bacteria owing to expression of
gene III during induction and thus ahigher yield ofantibody. Both
the supematant and the periplasmic fraction of bacteria, grown at
three different temperatures and harvested after two different time
intervals (growth at 20°C, 30°C and 37°C; induction during 4 h or
overnight), were first tested for the amount of functional scFv in
ELISA.
Five hundred millilitres of 2xTY/AIG [2xTY, supplemented
with 100 jg ml-' ampicillin and 2% (w/v) glucose] was inoculated
with E. coli TG1 harbouring MOC-31 or MOC-161 scFv in
pUC119-polyHIS6myc and bacteria were grown at 37'C to an
OD600 of 1.0. Bacteria were spun down, resuspended in 2xTY
containing 100 jig ml-1 ampicillin and IPTG to a final concentra-
tion of 1 mm and grown for4 h at 30°C while shaking. After4 h of
induction, bacteria were pelleted and periplasmic fractions were
prepared by resuspending the pellet in 8 ml of ice-cold TES
(200 mm Tris-HCl, 0.5 mM EDTA, 500 mm sucrose; pH 8.0),
adding 12 ml ofice-cold diluted TES (1:3 in water), and incubated
on ice for 30 min. Bacteria were spun down (4500 r.p.m., 15 min,
4°C) and the supernatant was collected. The cell pellet was resus-
pended again in 10 ml ofTES, 150 jl of 1 M magnesium sulphate
was added and the mix was incubated on ice for 30 min. Cells
were spun down again and the supernatant was added to the first
periplasmic preparation. EDTA was largely removed by means of
dialysis against 20 mm Tris-HCl, 100 mm sodium chloride (pH
8.0). The histidine-tagged scFv fragments were furtherpurified by
means of IMAC on Talon resin (Clontech, Palo Alto, CA, USA)
using elution with 100 mm imidazole, according to the manufac-
turer's protocol. Monomeric and dimeric forms of the scFvs were
separated by gel filtration chromatography (on a Superdex
column; Pharmacia) using a Biologic Apparatus (BioRad,
Hercules, USA). Different fractions were finally analysed by
means ofSDS polyacrylamide gel electrophoresis (SDS-PAGE).
Immunohistochemical analysis of scFv clones
Six-micron frozen sections (of normal colon epithelium,
melanoma and colon carcinoma) were cut, mounted on 3-amino-
propyltriethoxy silane (APTS)-coated glass slides, force dried on
air and fixed in acetone on ice for 15 min. Slides were force dried
on air again, bacterial periplasmic preparations were added [50%
(v/v) in PBS/1% bovine serum albumin (BSA)] and incubated for
30 min at 4°C. Slides were washed with PBS and bound scFv
antibodies were detected with the 9E10 antibody [50% (v/v)
hybridoma supernatant in PBS/1% BSA], peroxidase-conjugated
rabbit anti-mouse immunoglobulins [0.1% (v/v) in PBS/1% BSA]
and stained with diaminobenzidine (DAB)/hydrogen peroxide.
The slides were counterstained with haematoxylin.
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RESULTS
Comparison of the binding kinetics of different anti-
EGP-2 murine whole antibodies
One of the most important characteristics of antibodies is the rate
with which they detach from bound antigen, given by the off-rate
of the molecule (Koff). To select the antibody with the most
promising properties for tumour targeting, we set out to screen the
binding characteristics (and in particular the off-rate) of four
monoclonal antibodies directed to the pan-carcinoma antigen
EGP-2: 17-1A (and a chimeric version thereof), 323/A3, MOC-31
and MOC-161. The on-and off-rates of these (whole) antibodies
were determined using a BIAcore2000 (Figure 1 and Table 1). The
off-rate we measured for MOC-31 whole antibody is the lowest of
all antibodies tested; it would yield a half-life of the
antibody-antigen complex in solution of approximately 4 h. The
antibody that has been most often used for clinical applications,
17-lA, has an apparent off-rate which translates into an anti-
body-antigen complex half-life of less than a minute (Table 1).
Antibody MOC-161 has an apparent off-rate which is similar to
that of 323/A3 antibody. These off-rates are apparent values; they
are most likely underestimates of the real off-rates, because of the
bivalent nature of the antibodies causing rebinding events during
dissociation of antibody from the antigen surface (Nieba et al,
1996) and they are influenced by the experimental conditions used
to measure them. However, because all antibodies tested recognize
the same epitope on EGP-2 and the same experimental set-up was
used for all, the relative ranking will be correct.
To obtain absolute values for the binding kinetics of the best
antibody, MOC-31, it was necessary to determine those of the
monovalent antibody Bis-1, a bispecific antibody with one MOC-
31 binding site and one anti-CD3 site. The same antigen surface
bound approximately twice the amount (in RU) of Bis-1 when
compared with MOC-31 (Figure 1). This indicates that, despite the
use of a low-density EGP-2 surface, simultaneous binding ofboth
Fab arms was a very frequent event for all bivalent molecules,
which may be partially explained by the flexibility of the antigen
surface. As expected, the off-rate ofBis-1 was shown to be higher
(approximately fivefold: Table 1) than that ofMOC-31 antibody. It
can be concluded that, because MOC-31 has the lowest off-rate of
the antibodies tested, followed by MOC-161 and 323/A3 (Table
1), the MOC antibodies were the most promising starting points
for the cloning ofrecombinant antibody fragments.
Cloning of recombinant scFv antibody fragments
The genes encoding the variable parts of heavy (VH) and light
chain (VL) of the hybridomas MOC-31 and MOC-161 were
amplified by means of reverse transcriptase polymerase chain
reaction (RT-PCR) and assembled to form a scFv construct with a
15-residue (Gly4Ser)3 linker. The set of oligonucleotides used in
this study was similar to the one used by Clackson et al (1991),
with one important improvement: a redesigned set ofMVKBACK
primers was used, which was expanded to five oligonucleotides on
the basis ofthe collection ofmurine VK genes present in the Kabat
(1991) database (Kabat et al, 1991; Table 2). Extensive tests indi-
cate that this new primer set successfully amplifies over95% ofall
rearranged murine Vic genes (AR Pope personal communication).
For MOC-31, a 250-nt by-product was preferentially found during
amplification ofthe Vic domain when using a mix ofMVKBACK
primers. However, when all BACK primers were used separately
in different reactions, the band of expected size (approximately
340 nt) was predominantly found (>90% ofthe PCR product) with
primers MVKCBACK and MVKDBACK.
ScFv cassettes were cloned into phagemid vector pCANTAB6,
which allows expression either as fusion protein to the bacterio-
phage gene III product or as soluble scFv in a non-suppressor
strain of E. coli. For MOC-161, binding scFv were detected by
means of ELISA directly after cloning, in a frequency of 11/90.
This is a typical frequency when rescuing V-genes from
hybridomas (Clackson et al, 1991). For the MOC-31 hybridoma,
however, the initial screen did not reveal any active scFvs.
Therefore, a small scFv antibody repertoire (approximately 106
Table 3 Comparison of deduced amino acid sequences of anti-EGP-2 antibodies
(a) Heavy-chain V-genes
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Figure 3 Competition ELISA. Binding of MOC-31 (solid bars) and of MOC-
161 (hatched bars) scFv phage antibody to recombinant EGP-2 in the
presence of (A) no competing antibody, (B) an excess of an irrelevant
antibody (RFT5, an anti-CD25 hybridoma), (C) the MOC-31 whole antibody
and (D) the MOC-161 whole antibody. OD values (y-axis) are corrected for
background (which was approximately 0.08)
recombinant clones in size) derived from the MOC-31 hybridoma
was used for two successive rounds ofphage selection on antigen.
After two rounds, antigen-binding scFvs were found at a
t;t t frequency of 15 positives in 90 clones analysed. For each of the
two hybridomas, several binding scFv clones were further
analysed. Eventually, two representative clones were selected on
" .-:---'--.. the basis of DNA fingerprint patterns (MOC-31 scFv and MOC-
161 scFv respectively; data not shown), for which the data are
presented here.
The V-gene nucleic acid sequences of both antibody fragments
were determined using a semiautomated sequencer and sequences
were submitted to GenBank (accession numbers: U80187-
U80190). The primers used to amplify light chain genes were: for
MOC-31, MVKCBACK (consistent with the results ofthe primary
amplification of the light chain gene) and MJKIFONX; for MOC-
161, these were MVKDBACK and MJK5FONX. A comparison of
the amino acid sequences of MOC-31 and -161 with those of the
323/A3 and 17-lA antibodies is shown in Table 3 (for both MOC
antibodies, primer-encoded regions are depicted in lower-case
letters). Both hybridomas use very different VH and VK genes. The
MOC-31 VH and Vic gene segments are members of the Kabat II
and VII family respectively; for MOC-161, the designated families
are VII and XIV. Both antibody VH genes use the same germline J-
segment, being either JH2 or JH4 (both encoding a 'DY' sequence
in the C-terminal end ofthe CDR3 loop; Table 3). Besides these two
residues, the antibodies share an additional two residues ('KG') in
the C-terminal half of the VH-CDR3, which are most likely not
encoded by any D-segment.
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mlw
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Figure 2 Purification of scFv antibody fragments by IMAC and gel filtration
chromatography. (A) SDS-PAGE analysis of (1) MOC-31 induced bacterial
periplasm; (2) IMAC-purified MOC-31 scFv; (3-8) FPLC fractions of IMAC-
purified MOC-31 scFv (fraction 19-24); (9) molecular weight standards; (10)
MOC-31 -induced bacterial periplasm after IMAC purification. (B) OD280 profile
of the flowthrough after gel filtration of the different scFv preparations; MOC-
31 and MOC-161. (C) Protein standards 1-5 [1, dextran (V0); 2, albumin
(71.7 kDa); 3, ovalbumin (45.7 kDa), 4, chymotrypsinogen (20.2 kDa) and 5,
ribonuclease A (15.7 kDa)]
Production and purification of recombinant scFv
fragments
ScFv antibody production was induced in bacteria harbouring the
MOC-31 and -161 scFv cassettes in pUC119-polyHIS6myc. The
highest amount of antibody (as judged by titrating the fractions in
ELISA) was observed in the periplasm of bacteria after 4 h of
induction at 300C (data not shown). These conditions were there-
fore used to produce soluble scFv for purification. ScFv fragments
were then purified from a periplasmic extract of a large-scale
induced culture of bacteria by means of IMAC. This purification
procedure permitted both antibody fragments to be recovered in
highly pure form (purity > 95%; Figure 2). As scFv fragments
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Figure 4 Immunohistochemistry with anti-EGP-2 scFvs. Six-gm frozen sections of normal colonic epithelium, colon carcinoma and melanoma were stained with MOC-31 scFv (B, D, F) or without primary antibody (negative controls: A, C, E) respectively; sections were counterstained with haematoxylin. Similar
results were obtained with MOC-161 scFv (data not shown)
have been noted to be capable offorming dimers, the scFv proteins
were further purified by gel filtration chromatography to separate
monomers and dimers. The typical yield of purified monomeric
scFv antibody after IMAC and gel filtration was 100-200gg L-'
bacterial culture.
Binding analysis of the recombinant scFv antibody
fragments
The isolated scFv antibody fragments specifically bind EGP-2 in
ELISA (data not shown). Using competition ELISA, we could
demonstrate that the binding ofboth scFv antibodies, expressed as
plll fusions on the tip of filamentous phage, was competitively
inhibited by both of the original bivalent whole antibodies (Figure
3), whereas an irrelevant antibody (RFT5; an anti-CD25 antibody)
failed to inhibit binding ofthe recombinant antibody fragments to
EGP-2. This is an indication that the original epitope recognition is
retained by these scFvs.
By means of immunohistochemistry using soluble scFvs, we
further showed that both scFv antibody fragments specifically
bound EGP-2-positive tissues (Figure 4). As expected, both anti-
body fragments reacted with normal and malignant non-squamous
epithelia and did not stain malignant tissue reported to be negative
for the antigen (melanoma; Herlyn et al, 1979).
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The kinetics of binding of purified monomeric scFv antibody
fragments were determined using SPR in a BlAcore (Figure lB and
Table 1). The off-rate ofmonovalent MOC-31 scFv (3.4 x 104 s ')
only differs by a factor of less than 1.5 from that of the original
monovalent interaction (Bis-I antibody: 2.5 x 104 s; Table 1).
The monovalent MOC-31 scFv has a three times lower off-rate
than the bivalent 323/A3 antibody and is the best antibody of the
present series. The off-rate of MOC-161 scFv is significantly
higher (2.05 x 10-3 s-'), but still compares well to with those ofthe
whole (bivalent) antibodies 323/A3 (1.06 x 10-3 s-') and 17-lA
(38.2 x 10-3 S-1).
DISCUSSION
We compared the kinetics of binding of four well-characterized
antibodies directed to the pancarcinoma antigen EGP-2, using
SPR in a BlAcore (Figure IA and Table 1). The MOC-31 whole
antibody has by far the lowest apparent off-rate. To account for the
avidity of the bivalent MOC-31 antibody, we also determined the
kinetics ofbinding ofthe bispecific antibody Bis-1. As can be seen
in Table 1, the absence of a second EGP-2 binding site in Bis-1 is
reflected in a fivefold increase in off-rate (Koff = 2.5xl0-4 s') when
compared with MOC-31 whole bivalent antibody. As only
apparent kinetic constants were obtained, it is difficult to compare
our data with affinity values that have been reported for the
antibodies [17-lA: 7x107 M-1 (Herlyn et al, 1986) and 323/A3:
2xI09 M-l (Velders et al, 1995)]. However, dividing the on-rate of
the MOC-31 whole antibody by the off-rate of the monovalent
interaction (Bis-1) gives an affinity value of 4.2x108 M-l for this
antibody (Table 1). As the off-rate of the MOC-31 antibody is by
far the lowest and the on-rates of MOC-31 and 323/A3 differ only
by a factor of 2, the affinity of MOC-31 is expected to be higher
than that of 323/A3. Unexpectedly, however, the value we find for
MOC-3 1 is approximately fivefold lower than the one reported for
323/A3 (Velders et al, 1995), which may be due to the different
experimental set-up used (cell binding vs SPR analysis in a
BlAcore). We cannot exclude an effect of the different glycosyla-
tion of the recombinant antigen as compared with the antigen
present on human tumours on the kinetic parameters we measured.
However, there are strong indications that the differences in off-
rate we measured are genuine, as affinity differences were also
found by means of Scatchard analysis on a human cell line
(Velders et al, 1994).
The short half-life of the 17-lA-antigen complex (18 s for the
bivalent antibody) explains the inefficient in vivo tumour targeting
of this antibody (Velders et al, 1995), but also suggests that the
clinical responses obtained with this antibody may be largely
caused by factors other than tumour accretion (e.g. the immuno-
genicity of this antibody). Indeed, treatment of colorectal carci-
noma patients with an anti-idiotype antibody to the 17-1 A
antibody has been shown to result in a humoral as well as a cellular
immune response to the EGP-2 antigen (Fagerberg et al, 1995).
The use of the phage display system was necessary to retrieve
binding MOC-31 scFv clones; we had to perform two rounds of
phage selection of a mini-repertoire to find MOC-31 binding
scFvs. When cloning V-genes from hybridomas, a certain
percentage (typically 50-95%) of non-binding or non-functional
scFvs may be generated because of errors introduced during PCR
amplification ofthe genes, Ig mRNA contribution ofthe myeloma
fusion partner, alterations in the genes introduced by the primer set
used, cloning artefacts [e.g. deletions, recombinations, insertions
or frameshifts (for review, see Bradbury et al, 1995)] or a combi-
nation of these factors. Furthermore, the antigen-binding surface
might be slightly distorted or deformed by the introduction of a
linker sequence between the VH and VL domains. The use of
cloning vectors that allow expression ofboth secreted soluble scFv
molecules and of phage displayed antibodies (Hoogenboom et al,
1991) is therefore recommended for hybridoma V-gene cloning.
Using an in vitro model system (Roovers et al, in preparation), we
could estimate the enrichment factor of specific MOC-31 phage
over non-binding phage to be 150 per selection round, which
means that the estimated starting frequency offunctional MOC-31
scFv in the small library was at least 1 in 135 000. This very low
frequency of functional MOC-31 scFv necessitated the use of the
phage display system to retrieve binding clones, an observation
that has also been reported by others (Krebber et al, 1997).
The sequences ofMOC-31 and MOC-161 antibody V-genes are
different from the previously cloned anti EGP-2 antibodies (17-
IA: Caton, 1986; 323/A3: Velders et al, 1994). MOC-31 is very
similar to 323/A3 in both heavy and light chain sequences: there
are 11 amino acid differences for VH and three for Vic, with an
additional six and two silent mutations, respectively, in the non-
primer encoded sequences. The CDR3 of the heavy chain is
different, but equal in length; the CDR3 of the light chains are
identical. The MOC-161 VH, in contrast, shows a higher
homology to 17-IA (with 22 amino acid differences in the non
primer-encoded V-gene segment) than to MOC-31 or 323/A3; its
VK is very different from all other reported sequences (Table 3). It
is intriguing that all anti-EGP-2 antibodies studied here use VH
segments with a CDR3 length of six or seven residues. These
homologies may be a reflection of the fact that all four antibodies
bind to the same immunodominant epitope on EGP-2.
We have tested the specificity of the cloned antibody fragments
by means of an ELISA on six different antigens (EGP-2, tetanus
toxoid, BSA, Marvel, lysozyme and streptavidin: data not shown).
In addition, the fine specificity was confirmed using immuno-
histochemical staining of human carcinoma (Figure 4). Thus, the
cloning procedure itselfdid not alter the epitope recognition ofthe
antibodies.
To use the isolated scFvs in tumour-targeting studies, antibody
fragments with very low off-rates are required, as the loss of
avidity of these monovalent fragments combined with their rapid
clearance from blood leads to reduced retention in the tumour
(Adams et al, 1993). It can be calculated that for efficient tumour
retention, off-rates in the region of 10-5 S-l or better are required
(Schier et al, 1996), yielding a half-life of bound complexes of
19 h or longer. As the MOC-31 antibody V-genes were cloned in a
phagemid vector allowing expression on phage, it is possible to
affinity mature the antibody fragments (and in particular the off-
rate), for example by chain shuffling or by random mutagenesis of
the genes (for review, see Winter et al, 1994).
Alternatively, rather than affinity maturation, more avid mole-
cules such as bivalent or multivalent versions of MOC-31 scFv
may be made (for review, see Holliger et al, 1993). A second
antigen binding site in the same molecule creates a large avidity
effect, which makes the apparent affinity ofsuch bivalent antibody
species much higher. ScFv dimers, including non-covalently asso-
ciated diabodies, have indeed been reported to show superior
imaging characteristics of solid tumours than their monovalent
counterparts (Adams et al, 1993; Tai et al, 1995; Wu et al, 1996),
mainly because ofthe slower off-rate ofthese avid molecules. Our
cloned scFv antibody fragments already show a variable degree of
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dimerization, as shown by gel filtration chromatography of the
IMAC-purified scFv preparations (Figure 2). Non-covalent scFv
dimers or trimers of MOC-31 and MOC-161 may easily be made
by shortening the linker sequence separating the VH and VK
domains to fewer than ten residues to yield diabodies (Holliger et
al, 1993), or by deleting the linker completely to generate trimeric
molecules (Kortt et al, 1997).
In conclusion, the V-genes encoding these antibodies are useful
building blocks for the rational design and generation of
immunotherapeutics for the treatment of solid tumours. The anti-
bodies may, for example, be converted to fully human ones by
guided selection (Jespers et al, 1994), which will reduce the
chance of inducing a human anti-mouse antibody (HAMA)
immune response during repeated administration to patients.
Alternatively, bispecific antibodies (based on an anti-EGP-2
binding site and an anti-CD3 binding site) may, together with co-
stimulatory signals, be used to provide T cells with tumour speci-
ficity and cytotoxic potential (Kroesen et al, 1994). We have
recently synthesized such a bispecific molecule: a diabody
consisting of the MOC-31 V-genes in combination with the V-
genes of an anti-CD3 antibody. This diabody is capable of in vitro
retargeting T cells to lung cancer cells (Helfrich et al, 1998).
Additional antibody engineering is expected to lead to the devel-
opment of completely human immunotherapeutics based on the
EGP-2 antigen with improved affinity, dissociation rate, format
and, thus, pharmacokinetics to achieve maximum clinical efficacy.
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